• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Arthritis Center

Show Search
Hide Search
  • Disease Information
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Osteoarthritis
    • Gout
    • Osteoporosis
  • Patient Corner
    • Drug Information Sheets
    • Managing Your Arthritis
    • RheumTV – Patient Education Video Library
  • Our Research
    • Patient-Centered Outcomes Research
    • Current Research Studies
    • The Camille Julia Morgan Arthritis Research and Education Fund
  • About Us
    • Appointment Information
    • Contact Us
    • Our Faculty
    • Our Staff
    • Rheumatology Specialty Centers
  • Donate
Home / Arthritis News / Is Doxycycline Effective in the Prevention and Treatment of Lyme Disease?

Is Doxycycline Effective in the Prevention and Treatment of Lyme Disease?

April 13, 2005 By Arthritis Center

Lyme disease in humans is caused by infection of Borreli burgdorferi transmitted by the bite of an Ixodes scapularis. The disease is treatable at all stages, with either oral or intravenous antibiotics. In these two studies, doxycycline therapy is assessed, both as a preventative and as a treatment of Lyme disease.

Study 1: Klempner, et al (N Eng J Med 345:88, 2001) assessed whether a prolonged treatment of antibiotics would be efficacious in patients with documented Lyme disease who have with persistent musculoskelelal pin and/or neurocognitive symptoms despite the recommended course of antibiotic treatment. Patients were randomized to receive either intravenous ceftriaxone (2g qd) for 30 days followed by doxycycline (200mg qd) for 60 days, or matching intravenous and oral placebos. 78 patients were seropositive for B. burgdorferi and 51 were seronegative. An improvement in Medical Outcomes Study (MOS) 36-item Short-Form General Health Survey (SF-36) was used to assess efficacy.

The study was discontinued after the interim analysis of 107 patients found no differences between patients receiving prolonged antibiotic treatment and patients receiving placebo. No differences were observed between the seropositive and seronegative patients. No evidence of persistent infection with B. burgdorferi was found in the serum or cererospinal fluid of any patient.

Study 2: Nadelman, et al (N Eng J Med 345:79, 2001) conducted a randomized, clinical trial to determine if prophylatic treatment with a single dose of doxycycline would prevent Lyme disease following a I. scapularis tick bite. 482 subjects who had removed an attached I. Scapularis tick from their body within the previous 72 hours were treated with either a single dose of 200mg doxycycline or a placebo. Evaluation included serum antibody tests, blood cultures, and detection of erythema migrans at the site of the tick bite.

Erythema migrans developed a median of 12 days after removal of the ticks in 1 of 235 (0.4%) subjects who received doxycycline compared to 8 of 247 (3.2%) subjects in the placebo group. 7 of these 9 subjects with erythema migrans also had laboratory evidence of Lyme disease. In placebo-treated subjects, erythema migrans was significantly more likely to occur following bites from nymphal ticks that had been attached for > 72 hours when compared to adult tick bites and ticks attached for < 72 hours.

Conclusion: The data from these two studies indicate: 1) patients with chronic musculoskeletal pain and or neurocognitive symptoms that persist after antibiotic treatment for Lyme disease do not improve with a prolonged course of antibiotics (either IV or oral); 2) early treatment (within 72 hours of tick bite) with a single dose of 200 mg doxycycline is effective in preventing Lyme disease.

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Arthritis Center

Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.

Use of this Site

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

Recent News

Exercise Tips for Arthritis Patients

How Does Exercise Affect my Joints? How Frequently Should I Be Exercising? Should I Lose Weight for Exercise to be

Risks and Benefits of Biologic Medications

Victoria Ruffing, RN, BC, Director of Patient Education at the Johns Hopkins Arthritis Center, shares the risks and benefits of biologic for

How to Manage Rheumatoid Arthritis Flares

Through research, doctors have a clearer understanding of how flares can impact a patient on a personal and emotional level. Dr. Uzma Haque

Complementary & Alternative Medicines for Psoriatic Arthritis

There are many complementary & alternative medicines and practices that have been found to be beneficial in curbing arthritis pain,

I can’t be a runner because I have Rheumatoid Arthritis (RA), right?

Dr. Manno discusses running and Rheumatoid Arthritis. Is it an option for the RA patient?

News Categories

  • Ankylosing Spondylitis News
  • Fibromyalgia News
  • Gout News
  • Lupus News
  • Osteoarthritis News
  • Osteoporosis News
  • Psoriatic Arthritis News
  • Rheumatoid Arthritis News
RheumTV Logo

Rheum.TV is an informational platform created to educate patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit Rheum.TV

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube

Johns Hopkins Medicine

© 2023 Johns Hopkins Arthritis Center
Patient Privacy